Cycle Syncing Skincare: Developing and Substantiating Cycle Sets

Cycle Syncing Skincare: Developing and Substantiating Cycle Sets

June 5, 2026

9

Jorit Tessmann

Jorit Tessmann

CEO & Founder at Labtree GmbH

Cycle syncing skincare aligns a skincare routine with the phases of the menstrual cycle, typically as a set of several products with different focuses. For brands, the concept is viable if the phase logic only extends as far as the scientific evidence supports, advertising claims remain strictly cosmetic, and each product in the set is developed as its own tested formulation. What is primarily supported by evidence are premenstrual blemishes and barrier differences between individual phases, not four fixed skin conditions.

This article assesses the current state of research, outlines the boundary between cosmetic and medicinal claims under EU law, and describes the formulation, testing, and filling considerations that a multi-phase product set entails.

The topic is short and compact

Evidence mainly supports premenstrual blemishes and barrier differences between the ovulation and mid-luteal phases, rather than four fixed skin conditions.

A two-piece set consisting of basic care and a premenstrual product can be substantiated more tightly than four phase products and halves the number of formulations.

Claims regarding hormones or the treatment of acne are not considered cosmetic; substantiated claims about the appearance and condition of the skin are permitted.

The Labtree minimum order quantity, typically 1,500 units, applies per product—meaning for each formulation in the set individually.

Each phase product requires its own stability testing, challenge test, safety report, product information file, and CPNP notification.

So läuft die Entwicklung bei Labtree

1

Konzeptionierung

2

Bemusterung – Standardmuster in 24 h

3

Individualisierung

4

Prototyping

5

Produktion

White Label 2–3 Monate · Private Label 3–6 Monate · Produktion ab 1.000 Stück

What does research show about skin during the menstrual cycle?

Research supports individual cycle-dependent skin changes, but not a fixed four-phase pattern. The worsening of blemishes before menstruation is the best documented. In a survey of 105 women at a dermatology practice in New York (Geller et al., 2014), 65 percent stated that their acne worsens with menstruation. Of the affected women, 56 percent reported the flare-up in the week before menstruation, and 17 percent during menstruation. In the 18 to 29 age group, 68 percent reported such flare-ups, compared to 42 percent between the ages of 30 and 50. The authors themselves point out the limitations: a single practice, retrospective self-reporting, and predominantly young participants.

Measurement data on barrier function does exist, but it is scarce. A study involving 36 women of reproductive age (Cvjetković Nikoletić et al., 2025) measured transepidermal water loss (TEWL) in the ovulatory phase and the mid-luteal phase; the team determined ovulation using urine LH test strips. In the mid-luteal phase, TEWL was significantly higher, while skin hydration was higher in the ovulatory phase. The authors explicitly describe the existing data as contradictory.

A scoping review of 26 studies (Nguyen et al., 2024) confirms this gap. Most of the included papers deal with skin temperature, blood flow, and perspiration; for skin hydration and elasticity, only one study met the inclusion criteria in each case. The hydration study with 51 participants found no significant change in skin hydration across the early follicular phase, late follicular phase, and mid-luteal phase, and it observed only a single cycle, even though individual cycles can vary.

What this means for product development

  • The best supported distinction, albeit predominantly through survey data, is between premenstrual skin prone to blemishes and the remaining days of the cycle.

  • A more detailed four-phase logic serves as an organizational principle for the product range, not as a scientifically proven skin condition.

  • Marketing claims are built on skin conditions, not on calendar days.

How many phase products does a cycle set need?

The number of products should follow the evidence, not the number of cycle phases. A set of four phase products reflects a logic that can be supported by studies for two phases, and relies on assumptions for the rest. A two-part set consisting of a basic care product and a product for the premenstrual days can be more closely evidenced and reduces development and volume requirements. The table shows how sparse the evidence is for each phase:

Cycle phase

Study evidence

Possible formulation focus

Menstruation

A smaller proportion of respondents report blemishes during their period; no consistent barrier data

Low-irritation barrier care, little or no fragrance

Follicular phase

Scant phase-specific data

Lightweight moisturizing care

Ovulation phase

Higher skin hydration and lower TEWL than in the mid-luteal phase (one study)

Light texture, balancing care

Luteal phase, premenstrual days

Higher TEWL in the mid-luteal phase (one study); premenstrual blemishes reported most frequently

Barrier-conscious care for blemish-prone skin with moderately dosed active ingredients

A second point concerns irregular cycles. In a cross-sectional study of 197 women in Shanghai (Ma et al., 2023), women with irregular cycles had significantly lower skin hydration and higher TEWL than women with regular cycles; regularity was based on self-reporting, and hormone levels were not measured. For product design, it follows that every phase product must also be well-tolerated when used in a phase other than intended. High-dose acids or retinoids, which are only well tolerated under specific skin conditions, generally do not belong in a cycle set, but rather in a separately positioned product.

Which advertising claims are permitted for a menstrual cycle kit in the EU?

Substantiated claims regarding the appearance and condition of the skin on specific days of the menstrual cycle are permitted. Claims regarding hormones, the cycle itself, or the treatment of acne as a medical condition are not cosmetic. The legal basis is Art. 2(1)(a) of Regulation (EC) No 1223/2009: Cosmetic products are intended to be placed in contact with the external parts of the human body, with the exclusive or main view to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours. A claim suggesting a hormonal or therapeutic effect shifts a product toward the medicinal category. The European Commission notes on its borderline products page that classification is decided on a case-by-case basis, referring to the Borderline Manual on the scope of the Regulation.

Article 20 of Regulation (EC) No 1223/2009 and the common criteria of Regulation (EU) No 655/2013 apply to the wording. Under the evidential support criterion, the Annex requires adequate and verifiable evidence; studies relied upon must be relevant to the product and the claimed benefit. Under honesty, claims regarding efficacy must not extend beyond what the evidence supports. Therefore, a literature study on skin hydration during the ovulation phase does not substantiate a claim about your own product during this phase.

Example claim

Classification

“Cares for skin prone to blemishes before the period”

Cosmetic, product substantiation required

“Improves the visible appearance of the skin on the days before the period”

Cosmetic, can be substantiated with an in-use study

“Tailored to the four cycle phases”

Marketing claim; the phase logic must be plausibly justified

“Balances hormonal fluctuations”

Hormonal effect, not cosmetic

“Treats hormonal acne”

Therapeutic claim, borderline medicinal product

How advertising claims are reviewed and substantiated overall is described in the article Cosmetic Advertising Claims in the EU.

What formulation problems arise when multiple products are used in a routine?

A cycle set technically consists of several independent formulations that are used successively on the same skin and should be recognizable as a series. This gives rise to typical formulation challenges:

  • Shared base or separate systems: A shared emulsion base with phase-specific active ingredients keeps texture and sensory profile uniform and simplifies manufacturing. However, any addition of active ingredients can alter viscosity, pH value, and stability, which is why each variant is tested as its own formulation.

  • Preservation: Active ingredients for blemish-prone skin, such as organic acids, lower the pH value and can alter the effectiveness of some preservation systems. A system that works in the base is not automatically sufficient in the variant.

  • Skin compatibility over the month: If several products are used alternately, the cumulative load from fragrances, emulsifiers, and active ingredients increases. Fragrance-free or uniformly fragranced variants facilitate safety assessment and skin compatibility testing.

  • Distinguishable textures without a break: A lighter, mattifying treatment for the premenstrual days and a richer barrier care for menstruation must be sensorially distinguishable yet still fit into the same series. This affects viscosity, absorption behavior, and residue on the skin.

Barrier-conscious formulations for the premenstrual days technically overlap with care for adults with blemishes; the formulation logic behind this is described in the article on lipid-based care for hormonally induced blemishes.

Which tests does each product in the set require?

Each product in the set is a distinct cosmetic product with its own safety assessment. According to Art. 10 of Regulation (EC) No 1223/2009, the responsible person must ensure prior to placing on the market that the product has undergone a safety assessment and that a safety report has been prepared; in addition, a product information file pursuant to Art. 11 and a CPNP notification are required for each product. A set of four therefore means four dossiers, even if all formulations are based on the same base.

Test protocols per product

  • Stability testing of the formulation in the intended final packaging, with a particular focus on variants with pH-lowering active ingredients.

  • Preservation challenge test according to ISO 11930 for each water-containing variant, not just for the base.

  • Skin compatibility testing under dermatological supervision: not mandatory, but recommended as substantiation if the set is advertised with claims for sensitive or blemish-prone skin.

  • In-use study for cycle-related claims with a design that actually captures the phases: measurements on defined cycle days, determination of ovulation, for example via LH test as in the 2025 study, and a duration of at least one complete cycle, preferably two, because individual cycles vary.

The sequence and duration of these tests determine the schedule of a set more significantly than the laboratory work on the individual formulations. Which tests must be completed prior to launch is described in the article Stability and safety testing for cosmetics.

What does a set mean for minimum order quantity, packaging, and filling?

A set multiplies volume planning because each formulation is produced and filled individually. At Labtree, the minimum order quantity is generally 1,500 units per product, depending on product type, fill size, and packaging. A set of four phase products therefore means four minimum order quantities instead of one, and a set of two means two.

  • Fill sizes based on consumption: The cycle phases vary in length and differ from person to person. Identical fill sizes for all products in a subscription model lead to some products running out sooner than others. The fill size is therefore based on the expected consumption per phase and the period after opening.

  • Uniform packaging materials: Identical tubes, jars, or airless dispensers for all variants simplify procurement and filling; differentiation is achieved via color and label. The skin compatibility of each variant with the packaging material is nevertheless tested individually.

  • Labeling: Each product requires its own complete labeling according to Art. 19 of Regulation (EC) No 1223/2009, even if it is only sold in a set.

  • Replenishment: If one variant sells faster than the others, replenishment cycles diverge. A common base facilitates planning because bulk material for multiple variants is manufactured similarly.

As a B2B cosmetics developer and cosmetics manufacturer, Labtree covers formulation development, in-house laboratory work, sampling, manufacturability testing, and cosmetics production, transforming concepts into laboratory samples, manufacturable formulations, and finished cosmetic products. For a cycle set, early sampling is particularly relevant: samples of pre-qualified formulations typically leave the sample warehouse within 24 hours, allowing multiple phase products to be evaluated side-by-side early on. In white label, customized Labtree formulations with standard packaging are generally ready for delivery in 2 to 3 months; a private label new development usually takes 3 to 6 months to reach market readiness. The process is described on the page Have cosmetics developed.

How can a cycle set be positioned credibly?

How can a cycle set be positioned credibly?

How can a cycle set be positioned credibly?

A cycle set is credible when the communication describes the phases as orientation and ties product performance to skin conditions. Three decisions support this positioning:

  • Skin needs before the calendar: Product names describe the skincare focus, such as barrier care or care for blemish-prone skin; the cycle phase serves as an addition. This ensures the product remains understandable even with an irregular cycle.

  • Transparent study landscape: The target group is informed and reacts critically to exaggerated hormone claims. A phase logic that only goes as far as the evidence reduces the risk of legal warnings and inquiries in retail.

  • Differentiation from related categories: Cycle-based skincare is aimed at women with a regular cycle. For skin in hormonal transitional phases, different formulation priorities apply, as the article Perimenopause Skincare shows.

Commercially, the set format is viable primarily when each individual product also offers a clear skincare benefit on its own. The products can then be repurchased, sold individually, or transferred into a subscription without the range depending strictly on the phase logic.

Quellen

FAQ

Is cycle syncing skincare scientifically proven?

Partially. It is well documented that many women notice more blemishes before their period, and a 2025 study found differences in transepidermal water loss between the ovulation and mid-luteal phases. However, the data isn't sufficient to support four fixed skin conditions: the studies are small, often only observe a single cycle, and the authors themselves describe the existing evidence as contradictory.

Can a cycle set be advertised for hormonal acne?

Not as a treatment. Claims regarding the treatment of acne or balancing hormonal fluctuations exceed the cosmetic purpose set out in Art. 2 of Regulation (EC) No 1223/2009. Substantiated claims about skin prone to blemishes before a period are permitted; for more details, see the magazine article Cosmetic advertising claims in the EU.

How many products should a cycle set contain?

As many as can be substantiated and sold individually. A two-piece set consisting of basic care and a premenstrual product is directly supported by existing studies. Four phase products are possible, but would require a separate rationale for two of the phases and would double the testing and volume requirements.

Does the minimum order quantity apply to the set or to each product?

For each product. At Labtree, the minimum order quantity is generally 1,500 units per product, depending on the product type, fill size, and packaging. Each formulation in the set is produced and filled individually.

Does each product in the set need its own safety report?

Yes. Each product is a cosmetic product in its own right and requires a safety assessment with a safety report, a product information file, and a CPNP notification before being placed on the market. The magazine article "EU Cosmetics Regulation in Practice" details exactly what documents are needed.

Is a cycle set suitable for a subscription model?

Basically yes, provided the bottle sizes match the usage per phase and all products are used up within their shelf life after opening. Having identical sizes for phases of different lengths leads to uneven reordering. Every product should also be available for individual purchase.

Can this concept be applied to perimenopause?

Only to a limited extent, as cycles can become irregular during perimenopause, making a calendar-based phase approach less effective. Products named after specific skin needs make more sense. This category is covered in the magazine article Perimenopause Skincare.

Subscribe to our newsletter

Get more helpful information about cosmetics development.

Subscribe to our newsletter

Get more helpful information about cosmetics development.

Subscribe to our newsletter

Get more helpful information about cosmetics development.

Now discover more articles

Contact us!

>